N-乙基-4-哌啶甲胺 | 1220168-31-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-乙基-4-哌啶甲胺
• 英文名称: Ethyl-piperidin-4-ylmethyl-amine
• 英文别名: N-(piperidin-4-ylmethyl)ethanamine
• CAS: 1220168-31-9
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: RJASJOJQSLXLNG-UHFFFAOYSA-N

物化性质

• 沸点：
  201℃
• 密度：
  0.860
• 闪点：
  76℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  pentyl 4-((2S)-5-tert-butoxy-2-([(4-chloro-6-phenylpyridin-2-yl)carbonyl]amino)-5-oxopentanoyl)piperazine-1-carboxylate 、 N-乙基-4-哌啶甲胺 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 生成
  参考文献：
  名称：

  Part II: Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation

  摘要：

  Efforts to re. ne the SAR of the piperazinyl-glutamate-pyridines for more potent analogs with improved pharmacokinetic profiles are described. Exploring substituted piperidines and other ring systems at the 4-pyridyl position led to compounds with improved potency and pharmacokinetic properties over candidate I. In particular, compounds 4t and 5t were discovered with a 10-fold improvement over potency and improved pharmacokinetic profiles in both the rat and dog. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.110

文献信息

• [EN] 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS<br/>[FR] COMPOSÉS 1H-PYRAZOLO[4,3-D]PYRIMIDINE UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR DE TYPE TOLL 7 (TLR7)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021154665A1

  公开（公告）日：2021-08-05

  Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

  根据公式I，化合物可用作Toll样受体7（TLR7）的激动剂。这些化合物可用于癌症治疗，特别是与抗癌免疫疗法药物结合使用，或作为疫苗佐剂。
• PYRROLOPYRIDINE INHIBITORS OF KINASES
  申请人：Florjancic Alan S.

  公开号：US20110015173A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , R 1c , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及公式（I）的化合物或药用可接受的盐，其中R1a、R1b、R1c、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，该组合物对抑制Cdc7等激酶以及治疗癌症等疾病有用。
• 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME
  申请人：Frequency Therapeutics, Inc.

  公开号：US20200316089A1

  公开（公告）日：2020-10-08

  The present disclosure relates to 1,2-dihydro-3H-pyrazol-3-one compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.

  本公开涉及1,2-二氢-3H-吡唑-3-酮化合物及其使用方法，用于诱导干/祖细胞支持细胞的自我更新，包括诱导干/祖细胞增殖，同时维持子细胞中分化成组织细胞的能力。
• 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE
  申请人：Sekiguchi Yoshinori

  公开号：US20100081825A1

  公开（公告）日：2010-04-01

  Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

  本发明揭示了一种药物组合物，其包括一种由式(I)表示的化合物或其药学上可接受的盐作为活性成分，该化合物具有对黑色素浓集激素受体的拮抗活性。该药物组合物由于其对MCH受体的拮抗活性，可用于预防或治疗抑郁症、焦虑障碍（例如广泛性焦虑症、创伤后应激障碍、恐慌症、强迫症、社交焦虑症）、注意力缺陷障碍、躁狂、躁郁症、精神分裂症、情绪障碍、压力、睡眠障碍、发作、记忆障碍、认知障碍、痴呆、健忘症、谵妄、肥胖症、进食障碍、食欲障碍、过度进食、暴食症、食物恐惧症、糖尿病、心血管疾病、高血压、脂质代谢异常、心肌梗塞、运动障碍（例如帕金森病、癫痫、抽搐、震颤）、药物滥用和药物成瘾等疾病的预防或治疗。
• GAS CAPTURE PROCESS
  申请人：Yang Qi

  公开号：US20140127103A1

  公开（公告）日：2014-05-08

  A process for the capture of CO 2 from gas streams, the process including contacting a CO 2 containing gas stream with a compound including: a primary or non-sterically hindered secondary amine group and at least one tertiary amine or sterically hindered secondary amine group; wherein the primary or non-sterically hindered secondary amine and the nearest tertiary or sterically hindered secondary amine group are separated by a carbon chain including 3 or 4 carbon atoms and wherein the compound is a compound of Formula (I).

  一种从气流中捕集二氧化碳的过程，该过程包括将含二氧化碳的气流与包括以下化合物接触：一个一级或非立体阻碍的二级胺基和至少一个三级胺或立体阻碍的二级胺基；其中一级或非立体阻碍的二级胺和最近的三级或立体阻碍的二级胺基之间由包括3或4个碳原子的碳链分隔，并且该化合物是式（I）的化合物。